I Still Can’t Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug – Madison.com
Madison.com |
I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug
Madison.com JCAR015 was Juno's lead CAR–T cell therapy, a relatively new type of cancer treatment in which patient's T-cells are taken out of a patient's body, treated so that they're trained to attack the cancer cells expressing a specific protein, and then put … Vetr Inc. Upgrades Juno Therapeutics Inc (JUNO) to Buy Juno Therapeutics (JUNO) Getting Somewhat Favorable Press … |
